Product Information
TIAGABINE HCL 4 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $2.5246 per EA under NDC 00093503156. Its NADAC has been published 531 times since Aug 3, 2016.
FDA first approved this application on Sep 30, 1997. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
4 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093503156
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TIAGABINE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA020646FDA Approved
9/30/1997
TE Code
AB
On Market Since
6/3/2016
Pharmacological Classes
Price Statistics
The NADAC for TIAGABINE HCL 4 MG TABLET has been published 531 times since Aug 3, 2016, and over the history we have for it it has declined 51.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $2.5246 per EA |
|---|---|
| All-time high | $6.0403 (Aug 16, 2017) |
| All-time low | $1.6211 (Nov 19, 2025) |
| 52-week high | $2.5246 |
| 52-week low | $1.6211 |
| Median price | $3.6590 |
| Average price | $3.7157 |
| Largest weekly change | +43.0% (Mar 20, 2024) |
| Weeks tracked | 531 |
| Tracking since | Aug 3, 2016 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Tiagabine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anti-epileptic Agent class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TIAGABINE HCL 4 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TIAGABINE HCL 4 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $2.5246 per EA (NDC 00093503156), effective Sep 30, 2026.
How has the price of TIAGABINE HCL 4 MG TABLET changed over time?
Over the history we have for it, the NADAC for TIAGABINE HCL 4 MG TABLET has declined 51.4%. It has been tracked across 531 weekly CMS publications since Aug 3, 2016.
What are the highest and lowest recorded NADAC prices for TIAGABINE HCL 4 MG TABLET?
Since Aug 3, 2016, the NADAC for TIAGABINE HCL 4 MG TABLET has ranged from a low of $1.6211 (Nov 19, 2025) to a high of $6.0403 (Aug 16, 2017), with a median of $3.6590 per EA.
Are there cheaper alternatives to TIAGABINE HCL 4 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TIAGABINE HCL 4 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures TIAGABINE HCL 4 MG TABLET?
TIAGABINE HCL 4 MG TABLET (NDC 00093503156) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.